Related Experiment Video
Updated: Jul 10, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Inhibition of VEGF expression by targeting HIF-1 alpha with small interference RNA in human RPE cells
Peng Zhang1, Yusheng Wang, Yannian Hui
1Department of Ophthalmology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, PR China.
Background:
Vascular endothelial growth factor (VEGF) is upregulated by hypoxia and is a major stimulatory factor for choroidal neovascularization. The upregulation of VEGF expression in response to hypoxia occurs through hypoxia-inducible factor 1 (HIF-1), which is a transcription factor that regulates genes involved in the response to hypoxia. HIF-1 alpha is the inducible subunit of the HIF-1.
Aims:
To further define HIF-1 function in angiogenesis and to explore novel approaches to modulate choroidal neovascularization in age-related macular degeneration.
Methods:
In this study, we examined the response of human retinal pigment epithelium (RPE) cells to hypoxia and employed the small interference RNA technique to knock down gene expression of HIF-1 alpha in RPE cells.
Results:
We found that both the mRNA and protein levels of HIF-1 alpha in the RPE cells increased in response to hypoxia, followed by increasing expression of VEGF. Both the mRNA and protein levels of HIF-1 alpha and VEGF in the RPE cells were decreased dramatically after transfection with a HIF-1 alpha-specific small interference RNA vector.
Conclusion:
Our results suggest that HIF-1 may be involved in angiogenesis by controlling the expression of VEGF in vivo and provide a possible strategy for the treatment of angiogenesis by targeting the HIF-1 alpha in ischemic retinopathies.
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
Experimental RNAi
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

